Literature DB >> 31195067

Early change of prefrontal theta cordance and occipital alpha asymmetry in the prediction of responses to antidepressants.

Martin Bares1, Tomas Novak2, Premysl Vlcek3, Martin Hejzlar4, Martin Brunovsky5.   

Abstract

BACKGROUND: The study evaluated the effectiveness of EEG alpha 1, alpha 2 and theta power, along with prefrontal theta cordance (PFC), frontal and occipital alpha 1, alpha 2 asymmetry (FAA1/2, OAA1/2) at baseline and their changes at week 1 in predicting response to antidepressants.
METHOD: Resting-state EEG data were recorded from 103 depressive patients that were treated in average for 5.1 ± 0.9 weeks with SSRIs (n = 57) and SNRIs (n = 46).
RESULTS: Fifty-five percent of patients (n = 56) responded to treatment (i.e.reduction of Montgomery-Åsberg Depression Rating Scale score ≥ 50%) and 45% (n = 47) of treated subjects did not reach positive treatment outcome. No differences in EEG baseline alpha and theta power or changes at week 1 for prefrontal, frontal, central, temporal and occipital regions were found between responders and non-responders. Both groups showed no differences at baseline PFC, FAA1/2 and OAA1/2 as well as change of FAA1/2 at week 1. The only parameters associated with treatment outcome were decrease of PFC in responders and increase of OAA1/2 at week 1 in non-responders. There was no influence of the used antidepressant classes on the results. The PFC change at week 1 (PFCC) (area under curve-AUC = 0.75) showed only a numerically higher predictive ability than OAA change in alpha 1 (OAA1C, AUC = 0.64)/alpha 2 (OAA2C, AUC = 0.63). A combined model, where OAA1C was added to PFCC (AUC = 0.79), did not significantly improve response prediction.
CONCLUSION: Besides PFCC, we found that OAA1C/OAA2C might be another candidate for EEG predictors of antidepressant response.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alpha asymmetry; Antidepressants; Depressive disorder; Prediction of treatment outcome; Prefrontal theta cordance; QEEG

Mesh:

Substances:

Year:  2019        PMID: 31195067     DOI: 10.1016/j.ijpsycho.2019.06.006

Source DB:  PubMed          Journal:  Int J Psychophysiol        ISSN: 0167-8760            Impact factor:   2.997


  1 in total

1.  Prospective testing of a neurophysiologic biomarker for treatment decisions in major depressive disorder: The PRISE-MD trial.

Authors:  Ian A Cook; Aimee M Hunter; Marissa M Caudill; Michelle J Abrams; Andrew F Leuchter
Journal:  J Psychiatr Res       Date:  2020-02-26       Impact factor: 4.791

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.